Abstract
Today, personalized medicine is essentially based on individual “omics.” However there is a need to integrate this approach with a number of data such as pharmacokinetics, optimal dose and duration of drug treatments, age and gender differences, and drug interactions, which are relevant in terms of benefits and risks but are frequently unknown. This requires independent research that should be supported by governments in order to make personalized medicine a reality.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Temple JL, Ziegler AM, Graczyk A, Bendlin A, Sion T, Vattana K (2014) Cardiovascular responses to caffeine by gender and pubertal stage. Pediatrics 134:e112–e119. https://doi.org/10.1542/peds.2013-3962
Ruiter R, Burggraaf J, Rissmann R (2019) Under-representation of elderly in clinical trials: an analysis of the initial approval documents in the Food and Drug Administration database. Br J Clin Pharmacol 85:838–844. https://doi.org/10.1111/bcp.13876
Oscanoa TJ, Lizaraso F, Carvajal A (2017) Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol 73:759–770. https://doi.org/10.1007/s00228-017-2225-3
Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C, De Vittorio L, Marengoni A, Corrao S, Iorio A, Marcucci M, Mannucci PM, SIMI Investigators (2011) Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol 67:507–519. https://doi.org/10.1007/s00228-010-0977-0
Létinier L, Cossin S, Mansiaux Y, Arnaud M, Salvo F, Bezin J, Thiessard F, Pariente A (2019) Risk of drug-drug interactions in out-hospital drug dispensings in France: results from the drug-drug interaction prevalence study. Front Pharmacol 10:265. https://doi.org/10.3389/fphar.2019.00265
Nowogrodzki A (2017) Clinical research: inequality in medicine. Nature 550:S18–S19. https://doi.org/10.1038/550S18a
Castberg I, Westin AA, Skogvoll E, Spigset O (2017) Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand 136:455–464. https://doi.org/10.1111/acps.12794
MacLeod SM, Giles HG, Bengert B, Liu FF, Sellers EM (1979) Age- and gender-related differences in diazepam pharmacokinetics. J Clin Pharmacol 19:15–19. https://doi.org/10.1002/j.1552-4604.1979.tb01612.x
Yerman T, Gan WQ, Sin DD (2007) The influence of gender on the effects of aspirin in preventing myocardial infarction. BMC Med 5:29. https://doi.org/10.1186/1741-7015-5-29
Seeland U, Regitz-Zagrosek V (2012) Sex and gender differences in cardiovascular drug therapy. Handb Exp Pharmacol:211–236. https://doi.org/10.1007/978-3-642-30726-3_11
Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF (2004) Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44:499–523. https://doi.org/10.1146/annurev.pharmtox.44.101802.121453
Beeg M, Nobili A, Orsini B, Rogai F, Gilardi D, Fiorino G, Danese S, Salmona M, Garattini S, Gobbi M (2019) A surface plasmon resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. Sci Rep 9:2064. https://doi.org/10.1038/s41598-018-37950-4
Acknowledgments
The author thanks Judith Baggott for editing.
Funding
This work was funded by institutional funds from the Mario Negri Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that he has no conflicts of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Garattini, S. We are more than our omics. Eur J Clin Pharmacol 76, 1043–1044 (2020). https://doi.org/10.1007/s00228-020-02852-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-020-02852-w